In the past week, GNPX stock has gone up by 7.20%, with a monthly decline of -11.00% and a quarterly surge of 154.65%. The volatility ratio for the week is 9.57%, and the volatility levels for the last 30 days are 10.35% for Genprex Inc The simple moving average for the past 20 days is -12.54% for GNPX’s stock, with a -47.61% simple moving average for the past 200 days.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
Company’s 36-month beta value is -1.36.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GNPX is 8.27M, and currently, short sellers hold a 7.67% ratio of that floaft. The average trading volume of GNPX on December 27, 2024 was 9.43M shares.
GNPX) stock’s latest price update
Genprex Inc (NASDAQ: GNPX)’s stock price has dropped by -4.12 in relation to previous closing price of 0.93. Nevertheless, the company has seen a gain of 7.20% in its stock price over the last five trading days. prnewswire.com reported 2024-12-16 that Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA and Tecentriq in ES-SCLC Patients AUSTIN, Texas , Dec. 16, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the Safety Review Committee (SRC) has approved the opening of the Phase 2 expansion portion of the trial.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -36.35% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.82% of loss for the given period.
Volatility was left at 10.35%, however, over the last 30 days, the volatility rate increased by 9.57%, as shares sank -20.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +165.12% upper at present.
During the last 5 trading sessions, GNPX rose by +7.23%, which changed the moving average for the period of 200-days by -78.86% in comparison to the 20-day moving average, which settled at $1.0176. In addition, Genprex Inc saw -90.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -985.8 for the present operating margin
- 0.64 for the gross margin
The net margin for Genprex Inc stands at -980.82. The total capital return value is set at -13.71. Equity return is now at value -325.11, with -221.01 for asset returns.
Currently, EBITDA for the company is -31.06 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 262.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In a nutshell, Genprex Inc (GNPX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
